中国肿瘤生物治疗杂志2025，Vol.32Issue(6)：628-635,8.DOI:10.3872/j.issn.1007-385x.2025.06.009
PD-1抑制剂联合脐血NK细胞治疗晚期恶性实体瘤的安全性与疗效分析
Analysis of the safety and efficacy of PD-1 inhibitor combined with cord blood-derived NK cells in the treatment of advanced malignant solid tumors
摘要
Abstract
Objective:To preliminarily investigate the safety and efficacy of programmed death-1(PD-1)inhibitor combined with cord blood-derived natural killer cells(NK cells)in the treatment of advanced malignant solid tumors in an exploratory clinical trial.Methods:Three patients with advanced solid tumors treated at the Second Affiliated Hospital of Xi'an Medical University from December 2019 to December 2021 were enrolled.According to tumor type and CSCO guidelines,patients received multiple treatment cycles(21 days per cycle)consisting of standard chemotherapy,targeted therapy,or bevacizumab combined with PD-1 inhibitor.Umbilical cord blood-derived NK cells(8×107 cells per infusion)were infused at appropriate intervals during the treatment course.Target lesion size,tumor markers,levels of 12 peripheral blood cytokines,and lymphocyte subsets were assessed in each treatment cycle.Adverse events were also monitored throughout the treatment.Results:Following the treatment with PD-1 inhibitor combined with cord blood NK cells,2 patients achieved stable disease(SD,per RECIST 1.1 criteria),with durations of 118 days and 92 days,respectively.After NK cell infusion,patient#1 exhibited a marked decrease in the tumor marker CA199 to normal range and sustained for three follow-up periods;patient#2 showed significant reductions in tumor markers CA199,CA242,and CA724.Conclusion:The combination of NK cells with chemotherapy and PD-1 inhibitor demonstrates potential therapeutic efficacy for solid tumors.No severe immune-related adverse reactions were observed in the three patients enrolled in this study.关键词
程序性死亡蛋白-1(PD-1)/自然杀伤细胞(NK细胞)/实体瘤/免疫治疗/安全性Key words
programmed death-1(PD-1)/natural killer cell(NK cell)/solid tumor/immunotherapy/safety分类
医药卫生引用本文复制引用
樊云霞,樊伟军,高军,韩之海,黄炳俏,齐冰,陈寅嘉澍,奚凤,王丹,念沛沛..PD-1抑制剂联合脐血NK细胞治疗晚期恶性实体瘤的安全性与疗效分析[J].中国肿瘤生物治疗杂志,2025,32(6):628-635,8.基金项目
陕西省教育厅一般专项科研项目(No.21JK0881) （No.21JK0881）
陕西省科学技术厅自然科学基础研究计划(No.2022JQ-889) （No.2022JQ-889）
